HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alexander N Starodub Selected Research

Neoplasms (Cancer)

10/2017Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.
10/2017Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
8/2017Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
9/2015First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.
8/2014Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
8/2012Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.
7/2012A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Alexander N Starodub Research Topics

Disease

7Neoplasms (Cancer)
10/2017 - 07/2012
2Neutropenia
10/2017 - 09/2015
1Disease Progression
01/2022
1Prostatic Neoplasms (Prostate Cancer)
01/2022
1Colorectal Neoplasms (Colorectal Cancer)
10/2017
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
10/2017
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
08/2017
1Triple Negative Breast Neoplasms
07/2017
1Pancreatic Neoplasms (Pancreatic Cancer)
09/2015
1Adenocarcinoma
09/2015
1Exanthema (Rash)
07/2012
1Thrombocytopenia (Thrombopenia)
07/2012
1Mucositis
07/2012

Drug/Important Bio-Agent (IBA)

6Immunoconjugates (Immunoconjugate)IBA
10/2017 - 09/2015
5sacituzumab govitecanIBA
10/2017 - 09/2015
4Irinotecan (Camptosar)FDA LinkGeneric
10/2017 - 09/2015
3Bevacizumab (Avastin)FDA Link
08/2014 - 07/2012
3EverolimusFDA Link
08/2014 - 07/2012
1abirateroneIBA
01/2022
1enzalutamideIBA
01/2022
1labetuzumab govitecanIBA
10/2017
1Carcinoembryonic AntigenIBA
10/2017
1Cell Adhesion MoleculesIBA
10/2017
1Glucuronosyltransferase (UDP Glucuronosyltransferase)IBA
10/2017
1CamptothecinIBA
10/2017
1Type I DNA Topoisomerases (Topoisomerase I)IBA
10/2017
17-ethyl-10-hydroxycamptothecin beta-glucuronideIBA
10/2017
1Uridine Diphosphate (UDP)IBA
10/2017
1Immunoglobulin G (IgG)IBA
10/2017
1Biomarkers (Surrogate Marker)IBA
08/2017
1GemcitabineFDA Link
09/2015
1Membrane Glycoproteins (Membrane Glycoprotein)IBA
09/2015
1YttriumIBA
09/2015
11,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
09/2015
1MucinsIBA
09/2015
1Capecitabine (Xeloda)FDA Link
08/2014
1Protein Isoforms (Isoforms)IBA
08/2014
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
08/2014
1Messenger RNA (mRNA)IBA
08/2014
1Oxaliplatin (Eloxatin)FDA LinkGeneric
08/2014
1PanobinostatIBA
08/2012
1Dihydrotachysterol (AT 10)IBA
07/2012
1Panitumumab (Vectibix)FDA Link
07/2012

Therapy/Procedure

4Therapeutics
10/2017 - 09/2015
1Castration
01/2022
1Radioimmunotherapy
09/2015
1Drug Therapy (Chemotherapy)
09/2015